B- and plasma cell-targeting therapies for podocytopathies: state of the art and the New Gaslini Protocol

Clicks: 6
ID: 325801
2026
Free PDF
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal
Emerging

Ranked #43 of 129 articles by views in clinical kidney journal

Most read Least read

Bar heights use a square-root scale. Only the 120 most-read articles are drawn; the journal has 129 in total.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Sign in to mint
Abstract
Abstract Podocytopathies, including minimal change disease (MCD), focal segmental glomerulosclerosis (FSGS), and idiopathic nephrotic syndrome (INS), are traditionally classified by histology and corticosteroid responsiveness, but this framework does not capture their biological heterogeneity or underlying mechanisms. Over the past decade, the paradigm of podocyte injury has shifted from a T cell–centric model to a broader immunological framework in which B cells, plasma cells, and humoral immunity play a central role. The identification of circulating autoantibodies, including anti-nephrin antibodies, together with evidence of extrafollicular B-cell activation, supports a model in which humoral immune factors drive podocyte injury. Anti-CD20 therapies have improved outcomes in steroid-dependent and frequently relapsing disease, but their efficacy remains limited in steroid-resistant forms and post-transplant recurrence. This likely reflects incomplete depletion of tissue-resident B cells and persistence of long-lived plasma cells, supporting the need for strategies targeting multiple levels of the humoral immune axis. Recent studies suggest that combined targeting of CD20⁺ B cells and CD38⁺ plasma cells with monoclonal antibodies such as obinutuzumab and daratumumab may achieve deeper and more sustained disease control, including in refractory and recurrent cases. However, variability in treatment approaches across centers underscores the need for standardization. In this review, we summarize evidence supporting the role of humoral immunity in podocytopathies and discuss the strengths and limitations of B cell–directed therapies. We then propose a mechanistically-driven strategy, the New Gaslini protocol, integrating sequential CD20 and CD38 targeting to provide a unified framework for managing severe and relapsing disease.
Reference Key
openalex_W7203935646 Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors Paolo Cravedi, Agnese Spennacchio, Carolina Bigatti, Xhuliana Kajana, Gianluca Caridi, Andrea Angeletti
Journal clinical kidney journal
Year 2026
DOI
10.1093/ckj/sfag283
URL
https://doi.org/10.1093/ckj/sfag283
Keywords Keywords not found

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.